| scholarly article | Q13442814 |
| P2093 | author name string | Benjamin Andrick | |
| Joseph Vadakara | |||
| P2860 | cites work | Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial | Q50040577 |
| Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. | Q50985747 | ||
| Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. | Q52716122 | ||
| Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. | Q53816203 | ||
| Ibrutinib in Refractory Classic Hodgkin's Lymphoma. | Q54243205 | ||
| Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. | Q55000098 | ||
| Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial | Q56383260 | ||
| Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease | Q71714424 | ||
| Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse | Q95563584 | ||
| Mechanism of action of lenalidomide in hematological malignancies | Q21198872 | ||
| On Some Morbid Appearances of the Absorbent Glands and Spleen | Q24678559 | ||
| Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP | Q28252682 | ||
| Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report | Q28287838 | ||
| A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma | Q33397302 | ||
| Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. | Q33442092 | ||
| Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. | Q33632062 | ||
| ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned | Q34202155 | ||
| Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease | Q34534439 | ||
| Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders | Q34624766 | ||
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial | Q34637268 | ||
| Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) | Q34645722 | ||
| The involved field is back: issues in delineating the radiation field in Hodgkin's disease | Q34700776 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Epidemiology of Hodgkin's disease: a review | Q35777807 | ||
| A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma | Q35925674 | ||
| Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma | Q36356089 | ||
| Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. | Q36406979 | ||
| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | Q36822162 | ||
| Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. | Q37126978 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma | Q37279128 | ||
| Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). | Q38116144 | ||
| Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. | Q38386440 | ||
| AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy | Q38558611 | ||
| Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. | Q38875964 | ||
| Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis | Q38929198 | ||
| Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma | Q39132041 | ||
| Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes | Q40084076 | ||
| Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. | Q40457592 | ||
| Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. | Q41108261 | ||
| Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. | Q45070240 | ||
| Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group | Q47407977 | ||
| Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma | Q47563022 | ||
| Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma | Q47563175 | ||
| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group | Q48569127 | ||
| Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. | Q49912597 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 15-24 | |
| P577 | publication date | 2019-03-01 | |
| P1433 | published in | Chronic Diseases and Translational Medicine | Q50810645 |
| P1476 | title | Current advances in Hodgkin’s lymphoma | |
| P478 | volume | 5 |
| Q99571056 | Automatic Prediction and Assessment of Treatment Response in Patients with Hodgkin's Lymphoma Using a Whole-Body DW-MRI Based Approach | cites work | P2860 |
Search more.